11-36098353-G-A
Position:
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong
The NM_174902.4(LDLRAD3):c.346G>A(p.Ala116Thr) variant causes a missense change. The variant allele was found at a frequency of 0.000039 in 1,614,120 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Genomes: 𝑓 0.000072 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000036 ( 0 hom. )
Consequence
LDLRAD3
NM_174902.4 missense
NM_174902.4 missense
Scores
6
13
Clinical Significance
Conservation
PhyloP100: 3.65
Genes affected
LDLRAD3 (HGNC:27046): (low density lipoprotein receptor class A domain containing 3) Predicted to enable amyloid-beta binding activity. Predicted to act upstream of or within receptor-mediated endocytosis and regulation of protein processing. Predicted to be located in membrane. [provided by Alliance of Genome Resources, Apr 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -2 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.02145201).
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
LDLRAD3 | NM_174902.4 | c.346G>A | p.Ala116Thr | missense_variant | 4/6 | ENST00000315571.6 | NP_777562.1 | |
LDLRAD3 | NM_001304263.2 | c.199G>A | p.Ala67Thr | missense_variant | 3/5 | NP_001291192.1 | ||
LDLRAD3 | NM_001304264.2 | c.-134G>A | 5_prime_UTR_variant | 3/6 | NP_001291193.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
LDLRAD3 | ENST00000315571.6 | c.346G>A | p.Ala116Thr | missense_variant | 4/6 | 1 | NM_174902.4 | ENSP00000318607 | P1 | |
LDLRAD3 | ENST00000528989.5 | c.199G>A | p.Ala67Thr | missense_variant | 3/5 | 1 | ENSP00000433954 | |||
LDLRAD3 | ENST00000524419.5 | c.199G>A | p.Ala67Thr | missense_variant | 3/6 | 5 | ENSP00000434313 | |||
LDLRAD3 | ENST00000532490.1 | n.300G>A | non_coding_transcript_exon_variant | 4/5 | 4 |
Frequencies
GnomAD3 genomes AF: 0.0000723 AC: 11AN: 152198Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
11
AN:
152198
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000152 AC: 38AN: 250416Hom.: 0 AF XY: 0.000155 AC XY: 21AN XY: 135388
GnomAD3 exomes
AF:
AC:
38
AN:
250416
Hom.:
AF XY:
AC XY:
21
AN XY:
135388
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000356 AC: 52AN: 1461804Hom.: 0 Cov.: 31 AF XY: 0.0000358 AC XY: 26AN XY: 727208
GnomAD4 exome
AF:
AC:
52
AN:
1461804
Hom.:
Cov.:
31
AF XY:
AC XY:
26
AN XY:
727208
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000722 AC: 11AN: 152316Hom.: 0 Cov.: 33 AF XY: 0.0000805 AC XY: 6AN XY: 74488
GnomAD4 genome
AF:
AC:
11
AN:
152316
Hom.:
Cov.:
33
AF XY:
AC XY:
6
AN XY:
74488
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ExAC
AF:
AC:
18
Asia WGS
AF:
AC:
1
AN:
3478
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 21, 2023 | The c.346G>A (p.A116T) alteration is located in exon 4 (coding exon 4) of the LDLRAD3 gene. This alteration results from a G to A substitution at nucleotide position 346, causing the alanine (A) at amino acid position 116 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Uncertain
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Benign
.;.;T
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Uncertain
D
LIST_S2
Benign
T;T;T
M_CAP
Benign
D
MetaRNN
Benign
T;T;T
MetaSVM
Uncertain
D
MutationAssessor
Benign
.;.;N
MutationTaster
Benign
D;D;D
PrimateAI
Uncertain
T
PROVEAN
Benign
N;N;N
REVEL
Uncertain
Sift
Benign
T;T;T
Sift4G
Benign
T;T;T
Polyphen
0.26
.;.;B
Vest4
MutPred
0.52
.;.;Gain of glycosylation at A116 (P = 0.0286);
MVP
MPC
0.18
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at